Fisetin Dosage: How Much to Take, When, and Safety Notes (2026)

As we navigate the complexities of aging, the quest for interventions that genuinely promote healthspan continues to intensify. Fisetin, a naturally occurring flavonoid, has emerged as a compelling compound in this pursuit, particularly for its senolytic properties, the ability to selectively eliminate senescent cells, often dubbed “zombie cells.” For those exploring fisetin’s potential, a critical question immediately arises: what is the optimal dosage to achieve these promising benefits, and how do we ensure safety?

Understanding the nuances of fisetin dosage is paramount, especially as research progresses from preclinical models to human trials. This article aims to provide an evidence-based guide to fisetin dosage, timing, and safety considerations, drawing from the latest scientific findings available in 2026, to help longevity-focused individuals make informed decisions.

FisetinHub.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by linking to Amazon.com. We may earn a commission from qualifying purchases made through our links.

The Foundation: Preclinical Fisetin Dosage for Senolytic Effects

Much of our initial understanding of fisetin’s senolytic efficacy stems from compelling preclinical research. Studies in mice have consistently demonstrated that fisetin can selectively clear senescent cells, leading to significant improvements in various age-related pathologies and, notably, lifespan extension.

A landmark study published in eBioMedicine in 2018, which garnered considerable attention, utilized fisetin in naturally aged mice. Researchers administered fisetin at a dose of 100 mg/kg body weight per day for five consecutive days each month, observing a median lifespan extension of approximately 10% in the treated animals^[1]. The NIA Interventions Testing Program later tested fisetin in genetically heterogeneous UM-HET3 mice across three independent sites and found no significant lifespan extension in either sex at the dose and schedule used, so this should be read as a promising preclinical signal rather than a settled result^[2].

Translating these animal dosages directly to humans is complex due to differences in metabolism and bioavailability. However, these studies provide a crucial starting point, indicating that intermittent, high-dose administration might be more effective for senolytic clearance than continuous low-dose regimens.

Human Trials and Emerging Dosage Recommendations

While human clinical trials on fisetin are still relatively nascent compared to other longevity compounds, initial findings are beginning to shed light on effective human dosages. These trials are primarily focused on safety, pharmacokinetics, and preliminary efficacy in clearing senescent cells in specific tissues.

The trial most often invoked here did not test fisetin. The first-in-human senolytic pilot in idiopathic pulmonary fibrosis used dasatinib 100 mg/day plus quercetin 1250 mg/day, three days per week for three weeks, in 14 participants. Physical function improved significantly, but the study was open-label with no placebo group, and its effect on circulating senescence-associated secretory phenotype (SASP) markers was reported as inconclusive^[3]. The 20 mg/kg intermittent regimen widely quoted alongside it comes from fisetin trial protocols, not from published fisetin results.

The frailty finding that is often described as human is not. A 2025 Aging Cell study reported that intermittent oral fisetin (one week on, two weeks off, one week on) improved frailty and grip strength and reduced skeletal-muscle senescence in old mice, benchmarked against genetic clearance of senescent cells and the synthetic senolytic ABT-263^[4]. No fisetin frailty trial has published efficacy results in people.

What has been published in humans uses far smaller, sustained doses. A double-blind placebo-controlled trial gave 100 mg/day for seven weeks to 37 colorectal cancer patients undergoing chemotherapy; interleukin-8 fell significantly relative to placebo, while most other inflammatory and matrix-metalloproteinase measures did not^[5]. A 12-week randomized trial in 44 men with obesity used 200 mg/day alongside interval resistance-aerobic training^[6]. Both sit an order of magnitude below the gram-level pulses discussed in longevity communities, and neither was designed to measure senescent-cell clearance.

It is important to note that these human studies often employ a much higher single-day dose than what might be found in typical daily supplements, suggesting a “pulse” dosing strategy for senolytic effects.

Calculating Human-Equivalent Doses from Preclinical Data

When extrapolating from mouse studies, researchers often use body surface area (BSA) normalization to estimate human equivalent doses (HED). Using the standard conversion factor of 0.081, a mouse dose of 100 mg/kg becomes roughly 8.1 mg/kg in humans — about 570 mg/day for a 70 kg (154 lb) person, and about 810 mg/day for someone weighing 100 kg. The figure scales with body weight, so a single milligram number means nothing without the weight it was calculated for.

On that basis, a senolytic “pulse” scaled from the mouse protocol lands somewhere near 570–810 mg per day for a few consecutive days, depending on body weight. The 20 mg/kg figure that circulates in longevity communities — 1400 mg for a 70 kg person — is roughly double the body-surface-area estimate, and it comes from trial protocols rather than from any published human efficacy result. Neither number has been validated against a clinical endpoint in people.

Recommended Fisetin Dosing Strategies

Based on the current evidence, two primary dosing strategies for fisetin are emerging: intermittent senolytic pulsing and daily maintenance dosing for broader antioxidant and anti-inflammatory benefits.

Intermittent Senolytic Pulsing

This strategy is aimed at maximizing senescent cell clearance, mirroring the intermittent protocols that produced results in animal models. It involves taking higher doses for a short period, then pausing. It has not been shown to clear senescent cells or improve any clinical outcome in people.

• Dosage: 1000 mg to 1500 mg per day.
• Frequency: For 2-3 consecutive days, once per month or once every few months (e.g., quarterly).
• Rationale: This allows for the accumulation of fisetin to levels sufficient to induce senescent cell apoptosis, followed by a washout period. The intermittent nature may also prevent adaptation by senescent cells and maximize efficacy.

Daily Maintenance Dosing

While not directly linked to robust senolytic clearance in human studies yet, lower daily doses of fisetin may still offer significant benefits through its antioxidant, anti-inflammatory, and neuroprotective properties.

• Dosage: 100 mg to 500 mg per day.
• Frequency: Daily.
• Rationale: This approach aims to provide continuous support against oxidative stress and inflammation, potentially contributing to overall healthspan. Research into sustained low-dose senolytic effects is ongoing.

Many longevity enthusiasts combine these strategies, using a monthly senolytic pulse alongside a lower daily dose for general health support.

When to Take Fisetin and Bioavailability Considerations

Fisetin has relatively poor oral bioavailability, meaning a significant portion may not be absorbed into the bloodstream. This is a common challenge with many flavonoids.

• With Food: Taking fisetin with a fatty meal or alongside healthy fats (e.g., olive oil, avocado) can enhance its absorption. This is a general recommendation for fat-soluble compounds.
• Timing: There is no strong evidence suggesting a specific time of day is superior for fisetin intake. Given its relatively short half-life, splitting a daily dose (if taking more than 500 mg) might theoretically maintain more consistent blood levels, but for senolytic pulsing, the goal is a temporary high peak.
• Enhanced Formulations: Many “best fisetin supplement” options now incorporate bioavailability enhancers such as liposomal delivery systems or co-formulations with piperine (black pepper extract). These can significantly improve absorption, potentially allowing for lower effective doses or amplifying the impact of standard doses.

Fisetin Safety and Potential Side Effects

Fisetin has shown a good tolerability profile in preclinical work and in the small human trials published to date, which have run at 100–200 mg/day for seven to twelve weeks. Those trials are few, short, and were not designed to detect uncommon harms, so the safety record for gram-level intermittent pulsing rests on tolerability observations rather than on controlled safety data.

• Reported Side Effects: In human trials, side effects have been rare and mild, predominantly limited to occasional gastrointestinal upset (e.g., mild nausea, diarrhea) at very high doses. These effects typically resolve quickly.
• Drug Interactions: While fisetin is not known for significant drug interactions, its antioxidant properties could theoretically interact with blood thinners or other medications. Individuals on prescription medications, especially those affecting blood clotting or liver enzymes, should consult their physician before starting fisetin.
• Specific Populations: Pregnant or breastfeeding women, and individuals with severe kidney or liver disease, should avoid fisetin due to a lack of specific safety data in these populations.
• Long-Term Safety: Long-term human safety data, especially with consistent high-dose senolytic pulsing over many years, is still being accumulated. However, its natural occurrence in many fruits and vegetables suggests a generally low toxicity profile.

Comparing Fisetin to Other Senolytics and Flavonoids

Fisetin is often compared to other flavonoids and senolytics, particularly quercetin, which also exhibits senolytic properties. While both are powerful compounds, fisetin often shows greater potency in preclinical models.

Feature	Fisetin	Quercetin
Senolytic Potency (Preclinical)	Stronger efficacy in clearing senescent cells in many models.	Effective, often requires higher doses or co-administration with other compounds (e.g., dasatinib).
Bioavailability	Poor; benefits greatly from enhanced formulations.	Poor; benefits from enhanced formulations (e.g., phytosome, liposomal).
Neuroprotection	Strong evidence in preclinical models for cognitive benefits.	Also neuroprotective, but fisetin often highlighted for this specific benefit.
Anti-inflammatory	Potent anti-inflammatory effects.	Potent anti-inflammatory effects.
Human Trial Data	Emerging, with pilot studies showing senolytic activity and functional improvements.	More extensive human data for anti-inflammatory, allergy, and cardiovascular benefits; senolytic data is growing.

The choice between fisetin and quercetin often comes down to specific goals and individual response. Many individuals choose to incorporate both into their regimen, either together or on alternating cycles.

Finding the Best Fisetin Supplement: What to Look For

When searching for a fisetin supplement, quality and formulation are key to ensuring efficacy and safety. Given fisetin’s poor bioavailability, prioritizing enhanced formulations is often wise.

• Enhanced Bioavailability: Look for products that explicitly state “liposomal fisetin,” “phytosome fisetin,” or include “piperine” (black pepper extract) for improved absorption. These formulations can significantly increase the amount of fisetin that reaches your bloodstream.
• Purity and Third-Party Testing: Opt for brands that provide certificates of analysis (COAs) or state that their products are third-party tested for purity, potency, and absence of contaminants. This ensures you are getting the advertised dose without unwanted additives.
• Dosage Per Capsule: Consider the dosage per capsule to easily achieve your desired senolytic pulse or daily maintenance dose. This avoids having to take an excessive number of pills.

You can search for these attributes on platforms like Amazon: liposomal fisetin, fisetin supplement with piperine, or third party tested fisetin.

Conclusion

Fisetin stands as a promising senolytic and a valuable addition to a longevity-focused regimen. While research is ongoing, particularly in human trials, the existing evidence strongly supports its potential to clear senescent cells and promote healthspan.

For those seeking senolytic benefits, the intermittent pulsing strategy most commonly used in longevity communities is 1000–1500 mg per day for 2–3 days, once a month or quarterly. It is an extrapolation from mouse protocols and from trial dosing schedules, not a regimen shown to work in people. Daily maintenance doses of 100–500 mg sit closest to the range actually used in published human trials, though those trials measured inflammatory markers rather than senescent-cell clearance. Always prioritize high-quality, bioavailable formulations and consult with a healthcare professional, especially if you have underlying health conditions or are taking other medications.

Frequently Asked Questions (FAQ)

References

1. Yousefzadeh MJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine (2018). PMID 30279143
2. Harrison DE et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used. GeroScience (2024). PMID 38041783
3. Justice JN et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine (2019). PMID 30616998
4. Murray KO et al. Intermittent supplementation with fisetin improves physical function and decreases cellular senescence in skeletal muscle with aging: a comparison to genetic clearance of senescent cells and synthetic senolytic approaches (mouse study). Aging Cell (2025). PMID 40437670
5. Farsad-Naeimi A et al. Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients. Food & Function (2018). PMID 29541713
6. 12-weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin-1 and inflammatory markers in men with obesity: a randomized controlled trial. J Int Soc Sports Nutr (2026). PMID 42218768

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.